1068
Request Call Back
Contact
1068
Our division is led by a team of doctors who have pioneered many BMT procedures in the world and India
Enquiry Form
Search for Hospitals
Paediatric Bone Marrow Transplant Highlights
01
World-renowned bone marrow transplant specialists pioneering new techniques
02
High-volume centre for half-match transplants matching international success rate
03
State-of-the-art centre with 24x7 blood bank support, advanced infrastructure
04
Expertise in HLA-matching techniques optimising donor compatibility
05
Dedicated paediatric team, PICU and multi-disciplinary support for complex illnesses
06
Among top care centres for relapse or refractory blood cancer in children
Boosting immunity, changing lives
Transforming the Future Through Marrow Transplants
We specialise in catering to children suffering from thalassemia, sickle cell disease, cancers, immunodeficiency disorders of the blood
Expertise in half-match BMT, unrelated cord blood transplant and cell therapies that are not widely available, like CAR-T cell therapy
Our multidisciplinary approach ensures children get holistic and the gentlest treatment possible to ensure they continue to meet growth milestones
At Medanta, we currently averages 100 paediatric BMTs each year, making us a high-volume centre, driven to achieve excellence
Our Ailments
Team approach and compassionate care for holistic heart health.
Paediatric Brain Tumour
Paediatric brain tumours refer to abnormal growths of cells situated in a child’s highly fragile neural tissue. Unlike their adult counterparts, paediatric brain tumours result mainly from neurodevelopmental pathology and less from continual cell exposure to exogenous etiological agents over time. Paediatric brain tumours have vast variations in their histological types, location in the brain, and clinical behaviour. They can also be primary in the brain and spinal cord or secondary, where the tumour has metastasized solely from another organ.
Primary immunodeficiency
Primary immunodeficiency disorders (PI) are a group of over 300 genetic disorders that impair the immune system’s ability to defend against infections. Individuals with PI have defects in the cells or proteins that make up the immune system, leading to frequent, severe, or unusual infections. Symptoms can range from mild to severe and may include recurrent respiratory infections, gastrointestinal issues, skin infections, and failure to thrive in infants.
Diagnosing PI often involves a combination of clinical evaluation, family history, and specialized laboratory tests. Treatment varies depending on the specific disorder but may include immunoglobulin replacement therapy, antibiotics to prevent and treat infections, and in some cases, hematopoietic stem cell transplantation to correct the underlying immune defect.
Leukaemia
Leukaemia is a type of blood cancer that affects the white blood cells. It primarily starts in the bone marrow, the site where blood cells are produced. The most common types of leukaemia acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), and chronic myeloid leukaemia (CML). It is crucial to consult a doctor for accurate diagnosis and treatment options specific to the type you might have.
Aplastic Anaemia
Aplastic anaemia is a rare but serious disorder that disrupts the bone marrow's ability to produce enough blood cells. This malfunctioning bone marrow leads to deficiencies in red blood cells (causing fatigue), white blood cells (increasing infection risk), and platelets (raising the risk of bleeding). Aplastic anaemia has no universal cure, but treatments like blood transfusions and medications can help manage symptoms. In some cases, a stem cell transplant may offer a potential cure.
Inborn Errors of Metabolism
Inborn errors of metabolism (IEM) are a group of rare genetic disorders caused by defects in specific enzymes that affect the body's ability to convert food to energy. These enzyme deficiencies can lead to the accumulation of toxic substances or the deficiency of critical compounds, disrupting normal bodily functions. A few of them are Lysosomal storage disorders, Galactosemia, Maple syrup urine disease (MSUD), Phenylketonuria (PKU). Symptoms vary widely but may include developmental delays, weight loss, neurological issues, feeding difficulties, failure to thrive.
Diagnosis typically involves newborn screening, genetic testing, and metabolic assays. Treatment depends on the specific disorder and may include dietary modifications, enzyme replacement therapy, and medications to manage symptoms and prevent complications.
Inherited Blood Disorders
Inherited blood disorders such as Thalassemia and Sickle Cell Disease (SCD) significantly impact the production and function of haemoglobin, the protein in red blood cells responsible for oxygen transport.
Thalassemia affects the body's ability to produce haemoglobin. There are two main types: alpha and beta-thalassemia. The severity of symptoms varies depending on the type and number of gene mutations inherited. Individuals may experience mild to severe anaemia, leading to symptoms like fatigue, weakness, and shortness of breath. Management includes regular blood transfusions and chelation therapy to remove excess iron from the body.
SCD is a group of inherited disorders that cause abnormal haemoglobin. The most common form is Sickle Cell Anaemia. In SCD, red blood cells become sickle-shaped, stiff, and sticky, leading to a shortage of healthy red blood cells. These sickle cells can block blood flow in small vessels, causing severe pain and complications such as infections, acute chest syndrome, and stroke.
Both Thalassemia and SCD can be cured with Bone Marrow Transplant to improve quality of life and longevity.
Latest Technology
Smart systems and cutting-edge technology that drive seamless experiences.
- CD45RA Depletion
- Blood and Bone Marrow Stem Cell Collection
- TCR Alpha-Beta Depletion
- CAR T Cell Therapy
- Donor Lymphocyte Infusion
CD45RA Depletion
CD45RA Depletion is a specialised technique used in allogeneic hematopoietic stem cell transplantation and cell therapy. CD45RA is a marker found on naïve T cells, which have not yet encountered antigens. Depleting these cells from donor grafts helps to reduce the risk of graft-versus-host disease (GVHD), a common complication where the donor's immune cells attack the recipient's tissues. This technique is beneficial for patients with high-risk leukaemia, aplastic anaemia, and inherited metabolic disorders. In the context of CAR-T cell therapy, CD45RA depletion can be employed to enhance the safety and efficacy of the treatment by minimising the risk of GVHD. It is also applied in virus-specific T-cell therapies to selectively expand memory T cells that can combat infections post-transplantation. A technical complex procedure, it requires sophisticated equipment and expertise, making it available only in specialized centers
